Vincent Loon

Protego Bio is a clinical-stage company focused on the discovery and development of first-in-class small-molecule therapeutics that aim to reprogram protein folding for the treatment of various diseases. We are exploring monogenetic protein misfolding diseases that cause myopathy, cardiomyopathy, stroke, renal disease, retinal diseases, channelopathies, and various degenerative diseases. Our approach builds on the proven pharmacological chaperone strategy exemplified by tafamidis, which was discovered and developed by our cofounders, Dr. Jeffery W. Kelly and Dr. Richard Labaudinière, for the treatment of transthyretin amyloidosis.

Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

Protego Bio is a clinical-stage company focused on the discovery and development of first-in-class small-molecule therapeutics that aim to reprogram protein folding for the treatment of various diseases. We are exploring monogenetic protein misfolding diseases that cause myopathy, cardiomyopathy, stroke, renal disease, retinal diseases, channelopathies, and various degenerative diseases. Our approach builds on the proven pharmacological chaperone strategy exemplified by tafamidis, which was discovered and developed by our cofounders, Dr. Jeffery W. Kelly and Dr. Richard Labaudinière, for the treatment of transthyretin amyloidosis.

Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

FMO is the Dutch entrepreneurial development bank. As a leading impact investor, our mission is to create a more sustainable future through private sector investments in over 80 developing countries and emerging economies across the globe. Not only do we create and support jobs by investing in ambitious projects and entrepreneurs, we also focus on generating income and long-term business growth with the aim of making the world a better place than it was when we first started. By taking on investments that commercial parties are not willing to risk, we are able to serve those in more dire need of financial assistance, providing much-needed liquidity especially in the wake of the COVID-19 pandemic. We focus on three sectors that provide high development impact: financial institutions; energy; and agribusiness, food, and water. Our committed portfolio reaches over EUR 10.4 billion across over 80 countries, making FMO one of the larger bilateral private sector development banks in the world. Thanks to our 50+ years of success in these high-risk markets, we can generate more funding for customers, while contributing to the UN’s 17 Sustainable Development Goals, with an emphasis on reducing inequality, leading climate action change, and driving economic growth. To learn more about we provide capital for entrepreneurs in developing economies, please visit fmo.nl.

Forbion is a leading global venture capital firm with deep expertise in Europe. We invest in innovative biotech companies, managing just over €5 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. In addition, we leverage our biotech expertise beyond human health to address ‘planetary health’ challenges through our BioEconomy fund strategy, which invests in companies developing sustainable solutions in food, agriculture, materials, and environmental technologies.

SHIFT Invest, founded in 2009, is an impact venture capital fund. We turn investments into positive impact on climate and nature by investing in early-stage companies and supporting impact entrepreneurs to scale faster.   Based on our fund-level impact mission we strive to bring back the balance between nature and society by fighting climate change, loss of biodiversity and depletion of the resources of the planet. We do so by supporting and investing in innovative start ups and scale ups contributing to this mission in the themes: food & agriculture, green industries, energy and mobility. Together with our partners, we offer entrepreneurs an extensive network and insights into various sectors. Our involvement in the start ups and scale ups we invest in is above all about the support we can give to the people who run them. This support is based on our core qualities analytic, reliable, professional and our broad expertise. We are a diverse and experienced team committed to accelerate innovation by supporting the creation and acceleration of great companies. We work according to our values, professional, ambitious, entrepreneurial and fun.